The Chemical Biology Core Facility (CBCF) offers the infrastructure and expertise for assay development, small-molecule screening and use of medicinal chemistry to optimise compounds against novel targets for ‘biotool’ or early drug development.
The facility is set up as a collaboration between EMBL and German Cancer Research Center (DKFZ) to provide the infrastructure and expertise to open up small molecule development to research groups at these institutions.
|Major achievements and accomplishments|
|2004||Facility established in 2004 as a collaboration between EMBL and German Cancer Research Center (DKFZ).|
|2006||Spin-off of Elara Pharmaceuticals GmbH out of the facility to develop dual inhibitors targeting tumors.|
|2009||Computational chemistry established. Spin-off of Savira GmbH to develop and commercialise screening derived hits targeting influenza virus.|
|2013||Upgrade of the P3 Evolution pipetting system to an automation platform linking the Janus robot, liquid handler, Cytomat cell incubator and Envision reader|
|2014||Medicinal Chemistry lab opened|
|2015||Execution of 1536 HTS screen with patient derived cells on automation platform|
The overall direction of the facility is overseen by a steering committee which has senior members of staff from the EMBL and DKFZ. The projects are considered on a case-by-case basis, following preliminary evaluation for suitability and amenability to screening. The committee further reviews and assesses technical difficulties and determines priorities for new projects.
Please contact Joe Lewis to submit a project proposal.
Chemical Biology Core Facility
EMBL Heidelberg, Meyerhofstraße 1, 69117 Heidelberg, Germany
Phone: +49 6221 387-8935
Fax: +49 6221 387-8306
Email: General enquiries